![Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/08/2022.04.06.487285/F6.large.jpg)
Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv
![Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-016-2690-2/MediaObjects/277_2016_2690_Fig1_HTML.gif)
Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy | SpringerLink
![M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/758bf6ec-2e45-4986-b49c-d5af5bdbade9/bjh16159-fig-0002-m.jpg)
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library
![M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f1c31d20-3d42-4737-84f4-e7af5e705da5/bjh16159-fig-0005-m.jpg)
M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy - Lockmer - 2020 - British Journal of Haematology - Wiley Online Library
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig4_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink
![How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9074358b-bc40-44c8-81e3-051706bcfedc/bjh16011-fig-0001-m.jpg)
How I manage patients with follicular lymphoma - Casulo - 2019 - British Journal of Haematology - Wiley Online Library
![PDF) Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle PDF) Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle](https://i1.rgstatic.net/publication/336508262_Bendamustine_Plus_Rituximab_Is_Superior_in_Respect_of_Progression_Free_Survival_and_CR_Rate_When_Compared_to_CHOP_Plus_Rituximab_as_First-Line_Treatment_of_Patients_with_Advanced_Follicular_Indolent_a/links/5e0498664585159aa49abb35/largepreview.png)
PDF) Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle
![Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/e90cee05-31c1-4c5a-8b4c-2db9e6caeb21/bjh15814-fig-0001-m.jpg)
Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library
![The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton - The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -](https://onlinelibrary.wiley.com/cms/asset/4dc2614f-2257-4219-bb2f-62ae184912ae/bjh16555-fig-0003-m.jpg)
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -
![Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c880e7d6-3884-4edd-a1bc-b882d7c24b3c/gr2_lrg.jpg)
Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study - The Lancet Haematology
![Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-022-05037-w/MediaObjects/277_2022_5037_Fig1_HTML.png)
Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma | SpringerLink
![A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/748b56ba-a1ad-4d61-a1b0-d3c53629a4dd/bjh13637-fig-0001-m.jpg)
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma - Cohen - 2015 - British Journal of Haematology - Wiley Online Library
![Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population - Magnano - 2019 - British Journal of Haematology - Wiley Online Library Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population - Magnano - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b1cec494-ea17-4a37-b492-ecc067b7f18c/bjh15805-fig-0001-m.jpg)
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population - Magnano - 2019 - British Journal of Haematology - Wiley Online Library
![Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0d50658-ac6c-49ff-9ffc-eca30bafbafc/bjh15814-fig-0002-m.jpg)
Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma - Khashab - 2019 - British Journal of Haematology - Wiley Online Library
![Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2094227228/2077090889/gr1.gif)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial - The Lancet
![Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00277-020-04021-6/MediaObjects/277_2020_4021_Fig2_HTML.png)
Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma | SpringerLink
![The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton - The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -](https://onlinelibrary.wiley.com/cms/asset/5e721d81-fe43-40b7-b097-50ebf163eff7/bjh16555-fig-0002-m.jpg)
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival - Bishton -
![Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv Functional plasticity and recurrent cell states of malignant B cells in follicular lymphoma | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2022/04/08/2022.04.06.487285/F1.large.jpg)